The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies.

Blood Lymphat Cancer · 2025 · PMC12477285 · PMID 41030319

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significancep = 0.08so close (0.05 < p ≤ 0.1)

36 At week 24, the patients receiving two separate doses of pacritinib treated were pooled and demonstrated superior spleen volume reduction compared to BAT; however, although symptom improvement did not reach statistical significance (p = 0.08).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.